Summary

Eligibility
for people ages 18-65 (full criteria)
Location
at UCSF
Dates
study started
completion around

Description

Summary

This research study is testing an investigational research product called TRX103 as a possible treatment for individuals suffering from Crohn's Disease (CD). The primary purpose of this study is to learn how safe and effective different doses of TRX103 are when administered to individuals with CD.

Official Title

A Phase 1/2a, Open Label, Dose Escalation Study to Evaluate the Safety and Preliminary Efficacy of TRX103 in Subjects with Moderate to Severe Treatment-Refractory Crohn's Disease

Details

Please see our study website at https://www.cdclinicaltrial.com

Keywords

Crohns Disease, Tr1X, RESTORE, Crohns, autoimmune, IBD, CD, chronic inflammation, gastrointestinal tract, chronic diarrhea, intestinal ulcers, abdominal pain, Crohn Disease, Cyclophosphamide, TRX103

Eligibility

Locations

  • University of California, San Francisco accepting new patients
    San Francisco California 94158 United States
  • University of Iowa not yet accepting patients
    Iowa City Iowa 52242 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Tr1X, Inc.
ID
NCT06721962
Phase
Phase 1/2 research study
Study Type
Interventional
Participants
Expecting 22 study participants
Last Updated